Still feeling hungry on semaglutide? Here's what the evidence says

What the STEP 1 trial data tell us about appetite on semaglutide

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight plus a weight-related condition to semaglutide 2.4mg or placebo over 68 weeks. Average body weight fell by around 15% in the semaglutide group. Appetite reduction was a key mechanism, but the trial also showed that not everyone experiences the same suppression, some participants continued to feel hungry, particularly at lower doses early in the titration schedule.

That variability is biologically expected. Semaglutide acts on GLP-1 receptors in the hypothalamus, where appetite is regulated, and in the gut, where it slows how quickly food leaves the stomach. The strength of that signal differs between individuals based on receptor sensitivity, gut physiology and other factors that cannot be predicted before treatment begins. So if you are on semaglutide and still feeling hungry, you are not an outlier, and you are not doing anything wrong.

One pattern the trial data support is a within-week fluctuation. Because semaglutide is injected once weekly, plasma levels peak in the first couple of days and taper toward the end of the week. Many people notice hunger returning (sometimes noticeably) in the day or two before their next injection. This is sometimes called the end-of-week hunger dip, and it is worth logging so your prescriber can see whether it is consistent.

Why hunger often persists at the start of the titration schedule

The licensed titration for Wegovy begins at 0.25mg weekly and steps up gradually, with most people reaching the 2.4mg maintenance dose after around five months. This staged approach exists to reduce gastrointestinal side effects (nausea, vomiting, diarrhoea) not to achieve maximum appetite suppression from day one. At the lower doses, many people find hunger is largely unchanged from their baseline. That is expected, not a sign that the medicine is not working.

The NHS medicines page for semaglutide explains that the full therapeutic effect builds over time as the dose increases. Patients who are still feeling significant hunger mid-titration are often reassured that things shift at the higher maintenance doses, though how much depends on the individual.

It is also worth separating physical hunger from appetite-driven eating. Semaglutide tends to reduce the urge to eat for pleasure or out of habit more than it eliminates physical hunger signals entirely. Some people find they are less drawn to food generally but still feel stomach-level hunger at mealtimes. Both responses are real and worth discussing with whoever is managing your treatment. Adjusting meal timing, composition and frequency can make a genuine difference while the dose is still climbing.

Food choices that work alongside semaglutide, and those that undermine it

What you eat affects how hungry you feel on treatment, often more than people expect. Protein is the most relevant macronutrient: it prolongs satiety, supports muscle retention during weight loss, and tends to blunt the appetite rebound that can come later in the dose week. Aiming for a portion of protein at each meal (eggs, fish, legumes, Greek yoghurt, lean meat) is consistently endorsed by dietitians working in weight management.

Ultra-processed foods with high sugar content can work against the medicine's appetite-suppressing effect by driving rapid blood-sugar swings. Some people also find that liquid calories (juices, smoothies, alcohol) leave them hungrier than solid food of the same calorie count, because they bypass the gastric-slowing effect. Practical guidance on eating alongside Wegovy covers this in more detail, including fibre, hydration and meal spacing.

Hydration matters too. Mild dehydration produces sensations that are easy to misread as hunger. On semaglutide, where nausea can already suppress drinking, keeping fluid intake steady through the day is worth being deliberate about, plain water rather than caffeinated drinks, which can compound nausea at higher doses.

If you are managing food choices carefully and hunger is still a significant problem, that is exactly the kind of clinical signal that a prescriber review exists to address. You can read about what persistent hunger on semaglutide might mean for your dose and when to raise it.

When to speak to a prescriber, and what to tell them

Hunger on semaglutide is not automatically a problem to be fixed by increasing the dose. A prescriber will want to understand the pattern: Is it worse at certain times of day? Does it increase toward the end of the week? Is it accompanied by cravings or emotional eating? Is weight loss still happening despite the hunger? The answers shape whether the next step is a dose review, a change to meal strategy, or simply reassurance that the current dose needs more time.

At nume, every repeat supply is clinically re-reviewed before dispatch, your responses on the check-in form are read by a real prescriber, not processed automatically. If hunger is affecting your experience or your results, noting it clearly in that review is the most direct route to a useful clinical response. For broader questions about the Wegovy programme, our Wegovy treatment page covers eligibility, the titration schedule and what to expect at each stage.

Semaglutide is a prescription medicine that requires ongoing clinical oversight, and the cost of that oversight is something many people weigh up. You can find transparent Wegovy pricing information on our dedicated page. When you are ready to talk through whether treatment is right for you, checking your eligibility is the straightforward next step, a free consultation, reviewed the same day by a GPhC-registered prescriber.